KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) FCF Margin (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of FCF Margin data on record, last reported at 10.93% in Q4 2025.

  • For Q4 2025, FCF Margin fell 597.0% year-over-year to 10.93%; the TTM value through Dec 2025 reached 26.61%, up 3378.0%, while the annual FY2025 figure was 26.61%, 3378.0% up from the prior year.
  • FCF Margin reached 10.93% in Q4 2025 per VRTX's latest filing, down from 37.04% in the prior quarter.
  • Across five years, FCF Margin topped out at 49.47% in Q2 2022 and bottomed at 144.49% in Q2 2024.
  • Average FCF Margin over 5 years is 25.45%, with a median of 40.58% recorded in 2022.
  • Peak YoY movement for FCF Margin: plummeted -18760bps in 2024, then surged 17577bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 45.03% in 2021, then increased by 1bps to 45.37% in 2022, then plummeted by -85bps to 7.01% in 2023, then skyrocketed by 141bps to 16.9% in 2024, then plummeted by -35bps to 10.93% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 10.93% in Q4 2025, 37.04% in Q3 2025, and 31.28% in Q2 2025.